Extending clinical testing of familial melanoma cases of unknown etiology to additional targets from the PI3K/Akt family might support clinical management further, especially in the context of PI3K/Akt/mTOR inhibitors being actively considered as therapeutic approaches [92,93]. This evidence concerns the gene PIK3CD and melanoma.